CYCLICA

OVERVIEW

Cyclica Inc. (www.cyclicarx.com) offers a predictive analytics platform, **Ligand Express™**, which has been extensively used and validated through third-party organizations to develop safer and more efficacious therapeutics. Whether hypothetical, pre-clinical, clinical, or FDA-approved, Cyclica is able to offer insight and analysis into a small molecule's effect, in order to augment drug discovery pipelines and take assets from bench-to-bedside.

Additionally, Ligand Express™ can be thought of as a risk adjustment tool, helping to determine the likelihood of success for a small molecule earlier on in drug development.

SOLUTION

Cyclica's proprietary suite of computational algorithms, Ligand Express™, which is comprised of PROBE$_X$ (proteome-docking), SWITCH$_X$ (ligand effect prediction) & DIVE$_X$ (systems biology & drug-protein interactomes), evaluates and compares small molecules to predict how each will interact with the human body (i.e. human proteome). Additionally, our in-house database of structurally-characterized bacterial and viral proteomes provide further insight into how a drug will affect certain disease states.

VALUE PROPOSITION

- o   Drug Repurposing (*New Indications*)
- o   Drug Target Identification (*Mechanism-of-Action*)
- o   Lead Prioritization (*Best Candidate*)
- o   Adverse Effect Elucidation (*Toxicity Profiling*)

COMPETITION

We have distinguished ourselves by being the only computational platform able to screen a drug against all human proteins. Conventional technologies use 'virtual screening': many compounds screened against one protein, and are limited to disease-related proteins. In contrast, Ligand Express™ screens one compound against all proteins, providing insight into its consequences in the human body. In addition, Cyclica's market goes beyond the pharmaceutical industry, and can be applied to the personal care/cosmetic and nutraceutical markets with success.

TEAM EXPERIENCE

Cyclica's management team has >50 years of combined experience & expertise in bioinformatics, computational systems biology, pharmaceutical research & development, business strategy, corporate finance, and project management. In addition, Cyclica's scientific team has expertise in bioinformatics, medicinal chemistry, pharmacology/toxicology, biochemistry, biomedical communication, machine learning, drug discovery and personalized medicine.

Highlights:
Digital Drug Discovery & Evaluation
Founded in Toronto, 2010
10 employees (4 PhDs, 2 MBAs, 2 MScs)

Contact:
Naheed Kurji, CEO
416-304-9202
naheed.kurji@cyclicarx.com